Search This Blog

Thursday, May 7, 2026

Tandem Diabetes beats, reiterates guidance

 

Tandem Diabetes Care beats EPS and revenue estimates with Q1 2026 non-GAAP EPS -$0.30 and revenue $247.2M, reaffirms 2026 revenue and margin guidance

  • Q1 2026 revenue was $247.2M, increasing 5% year over year.
  • Non-GAAP EPS was -$0.30 in Q1 2026, improving 55% year over year.
  • Q1 2026 net loss reported totaled $20.4M during the quarter.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)